Evidence map›Paper›PMID 38755197›Full record

ArticleScientific reports2024

Reanalysis of cluster randomised trial data to account for exposure misclassification using a per-protocol and complier-restricted approach.

Suzanne M Dufault, Stephanie K Tanamas, Citra Indriani, Riris Andono Ahmad, Adi Utarini, Nicholas P Jewell, Cameron P Simmons, Katherine L Anders

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Wolbachia-carrying Aedes mosquitoes for preventing dengue infection.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suzanne M DufaultDivision of Biostatistics, Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco, USA. suzanne.dufault@ucsf.edu.
Stephanie K TanamasWorld Mosquito Program, Monash University, Clayton, Australia.
Citra IndrianiWorld Mosquito Program Yogyakarta, Center for Tropical Medicine, Yogyakarta, Indonesia.
Riris Andono AhmadWorld Mosquito Program Yogyakarta, Center for Tropical Medicine, Yogyakarta, Indonesia.
Adi UtariniDepartment of Health Policy and Management, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Nicholas P JewellDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Cameron P SimmonsWorld Mosquito Program, Monash University, Clayton, Australia.
Katherine L AndersWorld Mosquito Program, Monash University, Clayton, Australia.

Funding

Emerging methods and applications for test-negative studies of of infectious disease interventionsR01AI148127 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI JEWELL, NICHOLAS P · 2020 to 2023
$1.8M
NIAID NIH HHS R01 AI148127Wellcome Trust
6 · The paper itself

Abstract

The intention-to-treat (ITT) analysis of the Applying Wolbachia to Eliminate Dengue (AWED) trial estimated a protective efficacy of 77.1% for participants resident in areas randomised to receive releases of wMel-infected Aedes aegypti mosquitoes, an emerging dengue preventive intervention. The limiting assumptions of ITT analyses in cluster randomised trials and the mobility of mosquitoes and humans across cluster boundaries indicate the primary analysis is likely to underestimate the full public health benefit. Using spatiotemporally-resolved data on the distribution of Wolbachia mosquitoes and on the mobility of AWED participants (n = 6306), we perform complier-restricted and per-protocol re-examinations of the efficacy of the Wolbachia intervention. Increased intervention efficacy was estimated in all analyses by the refined exposure measures. The complier-restricted analysis returned an estimated efficacy of 80.7% (95% CI 65.9, 89.0) and the per-protocol analysis estimated 82.7% (71.7, 88.4) efficacy when comparing participants with an estimated wMel exposure of

Indexed as

AedesDengueWolbachiaAnimalsCluster AnalysisFemaleHumansMosquito ControlMosquito VectorsRandomized Controlled Trials as Topic

Identifiers

PMID38755197
PMCPMC11099120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.